Post-Traumatic Stress Disorder

Fort Lauderdale, FL

161 Post-Traumatic Stress Disorder Trials near Fort Lauderdale, FL

Power is an online platform that helps thousands of Post-Traumatic Stress Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Oxytocin for PTSD

Charleston, South Carolina
Posttraumatic stress disorder (PTSD) is a chronic, debilitating condition that disproportionately affects Veterans. Prolonged Exposure (PE) therapy is a "gold standard" treatment for PTSD. However, approximately one-third of Veterans fail to receive an adequate dose of treatment because they prematurely drop out of PE therapy. There is also room to improve PE treatment outcomes. Consistent with the VA Office of Research and Development initiative to develop effective treatments for PTSD, the proposed randomized clinical trial will examine the ability of oxytocin (as compared with placebo) combined with PE to reduce PTSD symptom severity, improve the rate of PTSD symptom reduction, and to enhance PE treatment retention and adherence. This two-site study will leverage the investments made in the nationwide rollout off PE therapy and has the potential to significantly improve mental health care among Veterans, advance the science in this area, and identify mechanisms underlying positive PTSD treatment response. Participants may choose to complete this research study via home-based telemedicine (HBT) care (i.e. service delivery to patients in their homes using consumer friendly, video-conferencing technology). HBT sessions will be delivered via standard desk, laptop computer, tablet, or smartphone using VA approved applications. All procedures that take place via telemedicine will be performed and completed as though they were in-person/in-office

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

185 Participants Needed

Therapy Methods for Post-Traumatic Stress Disorder

Charleston, South Carolina
Investigators' overall objective is to compare methods of identifying individuals who may be experiencing challenges in Cognitive Processing Therapy (CPT) and compare methods of intervening to optimize treatment retention and outcomes. Investigators' specific aims are: 1. to determine whether the use of CPT skills versus collaboratively considering switching to Present Centered Therapy (PCT) is more effective in improving outcomes for individuals experiencing challenges with CPT. Outcomes include post-traumatic stress disorder (PTSD) severity \[primary\], depression, functioning, and treatment retention; 2. to compare two approaches to identifying individuals in CPT in need of additional support during treatment; 3. to study the barriers and facilitators of implementing these intervention strategies. Finally, exploratory aims will examine the stability of differences between treatment conditions, compare combinations of interventions tested, and examine moderators of intervention effects.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

280 Participants Needed

EEG Neurofeedback for PTSD

Charleston, South Carolina
The goal of this clinical trial is to learn if training with the Prism system can reduce PTSD symptoms in US military Veterans and civilians with PTSD. Prism is a form of neurofeedback training that uses EEG signals to promote self-regulation of brain function. The main question this study aims to answer is: Does Prism training lead to decreased PTSD symptoms in US Veterans and civilians when used in addition to usual PTSD treatment? Researchers will compare Prism training to a sham training (a look-alike training that does not provide real feedback on brain activity) to see if Prism training decreases PTSD symptoms. Participants will: * Complete two one-hour in-person training sessions a week for about 8 weeks (15 sessions) * Complete two booster training sessions one month and two months after finishing the main training course * Participate in three detailed interviews: one before training, a second after nine weeks of training, and a third one month after the last booster training session (about 20 weeks after the initial visit)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 65

250 Participants Needed

Combined Written Exposure and Cognitive Behavioral Therapy for Sexual Assault Survivors

Charleston, South Carolina
This study is for women who have experienced a sexual assault in the past six weeks and use alcohol. The research involves completing a five week behavioral treatment for stress and alcohol use. Participants will complete surveys during visits. Participants may also be asked to complete brief daily assessments on their smart phones.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Sex:Female

64 Participants Needed

Trauma Focused Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder

Charleston, South Carolina
The current study will evaluate TF-CBT delivered via tele-health for youth presenting with trauma symptoms via a randomized controlled trial. Goals of the current study are to examine the effectiveness of Tele-TF-CBT delivered by community providers in Puerto Rico in improving youth trauma outcomes. Goals are also to support the feasibility, acceptability, and engagement outcomes of Tele-health delivery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 18

80 Participants Needed

Partner-Assisted Therapy for PTSD

Charleston, South Carolina
PTSD occurs in up to 17% of post-9/11 US Service Members and is associated with long-term functional impairment, family problems, unemployment, and suicidality. Trauma-focused therapies (TFTs), such as Prolonged Exposure (PE), result in significant relief for many. Yet, TFTs are not equally effective for everyone. An important minority (\~40%) will retain their PTSD diagnoses after treatment, and many discontinue treatment prematurely, especially post-9/11 Service Members. TFTs are also more effective in addressing symptoms than psychosocial functioning. More work is needed to improve the consistency and potency of TFTs. Partnering with significant others may provide a powerful method for helping individuals get more out of their PTSD treatment. Observational research shows that relationship factors can help patients initiate, stay in, and experience greater benefit from PTSD treatment. Veterans that were surveyed experienced greater treatment gains when they shared more about their treatment with loved ones and when loved ones accommodated less for PTSD symptoms. Despite the promise of partner-involved interventions, there is no couples approach to PTSD treatment that has demonstrated superior outcomes to individual-only treatment models (i.e., TFTs). To address this gap, the investigators have completed a series of partner-assisted PTSD treatment studies, leading up the current proposal (Partnered PE, PPE). The investigators found that treatment completion rates were better than routine clinical care, and the treatment led to large improvements in participants' functioning, PTSD symptoms, and romantic functioning. For this proposed study, the primary objective is to conduct a randomized controlled trial (Research Level 3; larger-scale clinical trial) to test the superiority of PPE to standard PE among post 9/11 Veterans. The investigator's primary hypothesis is that PPE will lead to greater improvements in psychosocial functioning than standard PE. Secondary and tertiary aims examine posttreatment clinical outcomes (PTSD, depression) and intimate partner outcomes (relationship functioning, distress, caregiver burden, and psychosocial functioning), as well as examine strategies for PPE implementation. In exploratory aims, the investigators will examine the stability of group differences, treatment completion rates, the role military sexual trauma history, and treatment mechanisms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

420 Participants Needed

Sertraline for PTSD

Charleston, South Carolina
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

94 Participants Needed

Suvorexant for Post-Traumatic Stress Disorder

Charleston, South Carolina
PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4

40120 Participants Needed

Combined Therapy for Alcohol Use Disorder and PTSD

Charleston, South Carolina
The goal of this clinical trial is to test the efficacy of a novel integrative cognitive-behavioral intervention in patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD). Specific Aim 1: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing alcohol frequency (percent days drinking) and quantity (drinks per drinking day) as measured by the Timeline Follow-Back (TLFB). Specific Aim 2: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5). Specific Aim 3: Use ecological momentary assessment (EMA) to evaluate intervention effects on daily alcohol-related cognitions and behaviors through real-time associations with PTSD symptomatology and distress tolerance. Researchers will compare integrative CPT+RP with RP-alone to see if CPT+RP is more efficacious in reducing alcohol use and PTSD symptom severity.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

200 Participants Needed

Oxytocin + COPE Therapy for Alcoholism and PTSD

Charleston, South Carolina
The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure). To evaluate purported neurobiological mechanisms of change, we will employ functional magnetic resonance imaging (fMRI) at pre- and post-treatment.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

180 Participants Needed

Alcohol Treatment for Couples with PTSD

Charleston, South Carolina
Intimate partner violence (IPV) is a serious public health problem that results in significant health and economic burdens including mortality, morbidity, and poor treatment outcomes. A well-developed field of research suggests that alcohol misuse and posttraumatic stress disorder (PTSD) can lead to IPV. Individuals with PTSD and/or problematic drinking behaviors are at risk for IPV because of several factors that are common symptoms of PTSD. Because individuals with PTSD often drink alcohol to "self-medicate" or cope with distressing PTSD symptoms, PTSD co-occurs with alcohol misuse and alcohol use disorder at extraordinarily high rates. However, few studies have examined the combined effects of alcohol misuse and PTSD on any form of violence. This study will examine the effects of alcohol misuse and posttraumatic stress disorder (PTSD) on alcohol-related intimate partner violence (IPV). We will examine these associations among couples (N=70) in a controlled laboratory setting using validated, standardized methods in a 'real-world' settings using 28 days of ecological momentary assessment (EMA).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21+

140 Participants Needed

HOPE Therapy for Opioid Use Disorder and PTSD

Charleston, South Carolina
This study will test a therapy intervention, HOPE, for individuals with opioid use disorder and posttraumatic stress disorder. Interested individuals will need to be taking medications for opioid use disorder (e.g., suboxone, naltrexone, methadone). Interested participants will complete a 10-12 week therapy, and be asked to complete surveys.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

76 Participants Needed

COPEWeb Training for PTSD and Substance Use Disorder

Charleston, South Carolina
PTSD and substance use disorders (SUD) are two of the most common and debilitating mental health conditions afflicting military Veterans. PTSD and SUD frequently co-occur and are associated with poorer treatment outcomes. The investigators' team developed a trauma-focused intervention, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE), which is identified by the VA as a gold standard of behavioral healthcare. However, a critical barrier to ensuring that Veterans with co-occurring PTSD/SUD receive evidence-based treatment is a lack of provider training. This project directly addresses this critical gap by developing a new web-based training program for providers (COPEWeb).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

248 Participants Needed

Exposure and Response Prevention for Obsessive-Compulsive Disorder

Charleston, South Carolina
This trial will test a therapy called ERP, which helps people face their fears and stop doing habits that make them feel temporarily better but keep the problem going. It will focus on Veterans with OCD, including those who also have PTSD. The goal is to see if this therapy improves their daily functioning and quality of life.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

160 Participants Needed

mHealth CAARE Program for Traumatic Injury Recovery

Charleston, South Carolina
Nearly 300,000 U.S. children experience injuries that require them to be hospitalized this year. These children, and their caregivers, are at high risk for emotional and behavioral problems, as well as poor quality of life. Trauma centers in the US have good outcomes for survival and physical recovery, but they typically do not have programs to address the emotional and behavioral needs of families. The purpose of this project is to develop a service that achieves this and that can serve as a good model for trauma centers to use. This project will develop, evaluate, and test CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies) to address the behavioral and emotional needs of caregivers and children.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

60 Participants Needed

Suvorexant for PTSD-Related Sleep Disturbances

Charleston, South Carolina
Post-traumatic stress disorder (PTSD) is a common consequence of combat that can result in trauma-related hyperarousal and sleep disturbances. Poor sleep, one of the most common complaints in Veterans with PTSD, can be distressing, impair concentration and memory, and contribute to physical health conditions, such as metabolic syndrome, inflammation, and cardiovascular disease. The orexin neuropeptide system underlies both sleep and stress reactivity. Suvorexant, a drug that reduces orexin, improves sleep in civilians, but has not yet been tested in Veterans with PTSD. This study will test whether suvorexant can improve sleep disturbances and PTSD symptoms in Veterans. Suvorexant may benefit Veterans by improving sleep quickly while also reducing PTSD symptoms over the long term, and with fewer side effects that were common in previous medications used to treat these conditions. Improving Veterans' sleep and PTSD symptoms could lead to better emotional and physical well-being, quality of life, relationships, and functioning.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

144 Participants Needed

Transdiagnostic Behavior Therapy for Depression and PTSD

Charleston, South Carolina
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive/anxiety disorders, including posttraumatic stress disorder. The proposed research seeks to evaluate the efficacy of TBT by assessing psychiatric symptomatology and related impairment outcomes in Veterans with depressive/anxiety disorders via a randomized controlled trial of TBT and existing DSTs in Veterans with major depressive disorder, posttraumatic stress disorder, and panic disorder. Assessments will be completed at pre-, mid-, and post-treatment, and at 6-month follow-up. Process variables also will be investigated.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

304 Participants Needed

Atomoxetine for PTSD

Charleston, South Carolina
Attention deficits (AD) frequently co-occur with posttraumatic stress disorder (PTSD). The presence of AD is associated with greater PTSD clinical severity and poorer clinical outcomes. Knowledge regarding the mechanism underlying this association is limited, though the emerging evidence has indicated that executive function deficit (EFD) is strongly correlated with AD and PTSD symptoms. While treatments developed for PTSD have existed for years, a substantial portion of individuals do not fully respond to conventional treatment. Accumulating evidence suggest that attention deficit (AD) and EFD may be a driving force for PTSD treatment resistance. However, treatment of executive impairment in PTSD is very limited. As a result, untreated co-occurring AD and EFD in PTSD poses severe negative impacts on patients' functional recovery, treatment outcomes, and quality of life (QoL). Given that up to 50% of patients do not respond well to the first-line pharmacological PTSD treatments, it is imperative to seek novel treatment strategies to improve EF that may improve both standard treatment response and QoL, social function. The proposed study directly addresses this knowledge gap by testing the efficacy of atomoxetine (ATX) in improving EF and attention among Veterans with PTSD, which will further improve Veterans' QoL and social function. ATX represents a promising novel candidate pharmacotherapy for individuals with PTSD. ATX is a non-stimulant selective norepinephrine reuptake inhibitor (SNRI), approved by the FDA for the treatment of ADHD. Studies suggest that ATX, unlike stimulants, lacks addictive properties and shows efficacy in the treatment of comorbid depression and anxiety, which is ideal in the treatment of PTSD. Data from the investigators' preliminary study provides encouraging support for the therapeutic potential of ATX in improving EF in Veterans with comorbid PTSD/ADHD. The investigators' recent research uncovered a higher rate of ADHD among Veterans with PTSD, and the comorbid AD symptoms were correlated with PTSD severity and poorer treatment outcomes. Treatment with ATX showed significant symptoms reduction in ADHD and improvement in inhibitory function in Veterans with ADHD/PTSD. In the proposed study, the investigators will focus on ATX in improvement of EF and attention, and further psycho-social life function and QoL. The investigators will (1) employ a randomized, double-blind design that will consist of 12 weeks of treatment with ATX or placebo medication; (2) use standardized, repeated dependent measures to rigorously assess AD and EFD symptomatology; (3) measure impairment in associated mental and behavioral health problems (e.g., attention deficit, depression, anxiety, suicidality, QoL, family/social functioning); and (4) use response inhibition task GoNogo, working memory and attention tests Digit Span and Trail Making to investigate the underlying pathophysiology of PTSD and prognostic indicators of treatment outcome. To achieve these goals, the investigators have assembled a multidisciplinary team with expertise in PTSD, ADHD clinical trials, and human laboratory paradigms who have successfully collaborated in the past and are uniquely qualified to implement this type of investigation. The proposed project is directly responsive to the mission of the VA-RRD "to maximize Veterans' functional independence, quality of life and participation in their lives and community." Successful completion of this study will provide a platform for a large multi-center trial to further confirm the important role of EF in PTSD treatment outcomes. The findings from this study will provide critically needed evidence to help inform clinical practice guidelines on the treatment of PTSD. The outcome of the proposed research will be significant, because it provides a knowledge base to allow for development of new PTSD intervention strategies. More importantly, this clinical trial may immediately benefit Veterans by enhancing their cognitive function, reducing AD related disability, and further improving quality of life for Veterans who suffer from PTSD.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4

160 Participants Needed

TRRP for Traumatic Injury in Adolescents

Charleston, South Carolina
Pediatric traumatic injury (i.e., injury of sudden onset and severity requiring immediate attention) is the leading cause of death and morbidity among US adolescents and are associated with mental health and health risk outcomes, including posttraumatic stress and depression (affecting between 19-42%), deficits in physical recovery, social functioning and quality of life, which if unaddressed, may contribute to increased use of health care services. The investigators partnered with three accredited Level I and II pediatric trauma centers to conduct a multi-site hybrid 1 effectiveness-implementation trial with 300 adolescent (ages 12-17) traumatic injury patients to assess the extent to which the Trauma Resilience and Recovery Program (TRRP), a scalable and sustainable, technology-enhanced, multidisciplinary stepped model of care, promotes improvement in quality of life and emotional recovery and gather preliminary data on the potential for TRRP to be implemented in other Level I trauma centers. Directly in line with NICHD's Pediatric Trauma and Critical Illness Research and Training (PTCIB) Strategic Research and Training agenda, this study will provide valuable data on the efficacy, preliminary effectiveness and potential for implementation of an innovative, cost-effective, sustainable technology-enhanced intervention designed to address the unique needs of adolescent injury patients and mitigate short- and long-term impact of injury on mental health, quality of life, and overall well-being.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 17

300 Participants Needed

CBT-I vs. MBTI for TBI-Related Insomnia

Eglin Air Force Base, Florida
This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 2-, 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

360 Participants Needed

Why Other Patients Applied

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

Expressive Writing for Racism

Auburn, Alabama
Racial and ethnic based stressors, such as microaggressions, are pervasive, distressing, and result in lasting negative repercussions for minoritized students at predominantly white institutions (PWIs). These racial and ethnic based stressors are experienced in addition to the universally experienced stressors of higher education. Negative repercussions of microaggressions include increased drop out or transfer rates, distress, fatigue resulting in decreased academic performance, and depression and posttraumatic stress symptoms. Expressive writing (EW) may be a scalable intervention for addressing the negative repercussions resulting from microaggressions experienced by minoritized students at PWIs. Previous research suggests that EW for stressful life events results in benefits such as reduced depression and posttraumatic stress symptoms, improved coping strategies, and reduced activity restriction. Despite such benefits, EW was not designed to specifically address microaggressions in a minoritized student population. Informed by the ADAPT-ITT model, our research group conducted a pilot study with similar procedures. This pilot study demonstrated the acceptability of an adapted version of the EW intervention titled Writing Wrongs (WW), as well as recommended future modifications for WW. In the current study we aim to conduct a randomized-controlled trial to establish the efficacy of WW in alleviating clinical symptoms. We hypothesize that WW will improve symptoms of racial and discriminatory trauma and symptoms of depression, anxiety, and posttraumatic stress over time and compared to an assessment-only condition. We will conduct exploratory analyses to examine short-term changes in affect within and across sessions and across conditions. We will recruit minoritized students enrolled at a PWI. Participants will complete a pre-intervention assessment prior to being randomized into the two conditions. Participants in the intervention condition will engage in three sessions of WW and complete measures of clinical symptoms across multiple time points (i.e., pre-intervention, immediately after the final writing session, one week after the final session). Participants in the assessment-only condition will be administered the same measures at the same timepoints and given access to the WW after completing the study. If found to be efficacious, WW has the potential to be widely disseminated to minoritized college students who experience microaggressions.
No Placebo Group

Trial Details

Trial Status:Recruiting

70 Participants Needed

MDMA-Assisted Exposure Therapy for PTSD

Atlanta, Georgia
Posttraumatic stress disorder (PTSD) is a debilitating disorder. While effective treatments exist, some patients fail to receive the full benefits. Alternative treatment approaches are needed. 3,4-methylenedioxymethamphetamine (MDMA) is a medicine associated with feelings of closeness and love for others, empathy, insightfulness, and feelings of peace or well-being. Recent research combining one or two doses of MDMA with psychotherapy has shown improvements in PTSD symptoms. For the present study, the researchers will investigate MDMA in combination with Prolonged Exposure therapy (PE), a gold-standard treatment for PTSD. All participants receive MDMA on the second day of a 10-day PE treatment program in which a PE therapy session occurs each day. This study will occur at the Emory Brain Health Center. Potential participants will be recruited via community advertising and mental health referrals. The research team will also collect psychophysiological data for exploratory analyses regarding how MDMA may improve PE treatment for PTSD. This is an important study as it is the first time MDMA will be combined with an evidence-based existing PTSD treatment. The study population will consist of people who meet the criteria for PTSD and are medically appropriate for MDMA administration.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 70

40 Participants Needed

cTBS for PTSD

Atlanta, Georgia
This project represents a unique collaborative opportunity to pursue the essential proof-of-principle demonstration that non-invasive interference of sensory cortical memory consolidation shortly after an emotional experience can attenuate the cued fear response and potentially reduce the risk of developing post-traumatic stress disorder (PTSD). If successful, the study results would anchor a potential advance in the treatment of patients after a traumatic event and seed future animal and clinical studies of emotional sensory cortical memory consolidation to reduce the prevalence and negative sequelae of PTSD.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

66 Participants Needed

tcVNS for PTSD

Decatur, Georgia
This study effects the effects of transcutaneous cervical vagal nerve stimulation (tcVNS) or a sham control on brain, physiology, and PTSD symptoms in Veterans with posttraumatic stress disorder (PTSD). Veterans undergo brain imaging and physiological measures in conjunction with traumatic scripts before and after three months of twice daily treatment with tcVNS or sham stimulation at home.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

80 Participants Needed

TMS for Post-Traumatic Stress Disorder

Atlanta, Georgia
The study will (1) assess feasibility of a TMS treatment in an underserved population; (2) determine if this TMS treatment protocol improves PTSD symptoms and biological markers of PTSD such as brain functioning and startle responses; (3) define new brain targets for future TMS studies; (4) provide the first data for individual differences, which will help personalize treatment for PTSD patients; (5) improve knowledge of the neurobiology of PTSD and treatment response.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 65

63 Participants Needed

Vagal Nerve Stimulation for Traumatic Brain Injury and PTSD

Decatur, Georgia
Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) are important conditions for the Veterans Administration (VA) that frequently occur together in combat Veterans from the conflicts in Afghanistan and Iraq. In many Veterans these become chronic, raising the risk the burden of neurotrauma can worsen over time. This study will examine a new intervention called non-invasive Vagal Nerve Stimulation (nVNS) and its effects on memory and symptoms of PTSD and mTBI as well as brain and physiology in Veterans with mTBI and PTSD.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55

100 Participants Needed

PTSD Screening for Pregnant Women

Atlanta, Georgia
This study will compare the effectiveness of two active screening interventions in improving post-traumatic stress disorder (PTSD) symptoms, maternal perinatal care utilization, satisfaction utilization of mental healthcare services, and maternal health and birth-related outcomes for Black pregnant women.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

804 Participants Needed

Estradiol Patch for Post-Traumatic Stress Disorder

Atlanta, Georgia
This study will test for effects of estradiol (E2) on PTSD symptoms and functional magnetic resonance imaging (fMRI) indicators of stress vulnerability, in naturally-cycling women who are not using hormonal birth control. Enrollment will be targeted to create three groups within two cohorts (early follicular phase and luteal phase): 1. PTSD: Women who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD 2. Trauma-Exposed (TC): Women matched for age and trauma exposure severity but without PTSD 3. Healthy Control (HC): Women matched for age, but without trauma history or psychiatric disorder (self-reported) Women will be recruited through Grady Trauma Project (GTP), a large longstanding study of civilian trauma and PTSD conducted at Grady Memorial Hospital in Atlanta, Georgia.

Trial Details

Trial Status:Recruiting
Age:18 - 35
Sex:Female

240 Participants Needed

DGB + tVNS for Post-Traumatic Stress Disorder

Decatur, Georgia
Post-traumatic stress disorder (PTSD) is a highly prevalent anxiety disorder that is associated with an increased risk of cardiovascular (CV) disease and hypertension. One potential mechanism is overactivation of the sympathetic nervous system (SNS), both at rest and particularly during stress. This study will evaluate whether 8 weeks of daily DGB therapy or transcutaneous vagus nerve stimulation (tVNS) therapy improves SNS activity at rest and during stress.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

120 Participants Needed

tDCS for Chronic Pain and PTSD

Atlanta, Georgia
The Veteran population has been known to deal with co-morbid chronic pain and PTSD. As a result, they use healthcare services at a higher rate than those Veterans with pain or PTSD alone which leads to an amplified burden on healthcare systems. tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. This study hypothesizes that our short-term therapy-focused treatment program coupled with tDCS administrations will aid in the reduction of chronic pain and PTSD symptoms. Secondly, the investigators intend to examine any relationships between BDNF reduction in reported pain and PTSD and related mental health symptoms. Subjects will be identified from the Emory Healthcare Veterans Program (EHVP-IOP) Veterans and Service members seeking psychiatric treatment for mental health issues including PTSD.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

38 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Post-Traumatic Stress Disorder clinical trials in Fort Lauderdale, FL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Post-Traumatic Stress Disorder clinical trials in Fort Lauderdale, FL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Post-Traumatic Stress Disorder trials in Fort Lauderdale, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Fort Lauderdale, FL for Post-Traumatic Stress Disorder is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Fort Lauderdale, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Post-Traumatic Stress Disorder medical study in Fort Lauderdale, FL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Post-Traumatic Stress Disorder clinical trials in Fort Lauderdale, FL?

Most recently, we added PROSOMNIA Sleep Therapy for Chronic Insomnia, Suvorexant for Post-Traumatic Stress Disorder and RISE for Domestic Violence to the Power online platform.

What is the new treatment for PTSD?

The two headline “new” approaches are MDMA-assisted psychotherapy—which has shown large symptom reductions in Phase-3 trials and could gain FDA approval soon—and the stellate ganglion block, an ultrasound-guided neck injection that can rapidly calm the nervous system and is already offered off-label by some pain specialists. Both are considered add-ons rather than replacements for proven trauma-focused talk therapies, and access currently means enrolling in a clinical trial for MDMA or seeing an experienced clinician for an SGB after discussing possible benefits, side-effects, and costs. If you’re interested, talk with a PTSD-trained mental-health professional to see whether one of these emerging treatments fits your situation.

What are the 7 symptoms of PTSD?

Clinicians group PTSD signs into four clusters, but popular summaries often point to seven tell-tale symptoms: intrusive memories or flashbacks, trauma-related nightmares, avoiding reminders, ongoing negative mood or beliefs, constant jumpiness/hyper-alertness, sudden irritability or anger, and trouble sleeping or concentrating. If several of these have lasted more than a month and are disrupting daily life, it’s time to talk with a mental-health professional because effective therapies and medications are available.

What is the difference between PTSD and clinical PTSD?

“Clinical PTSD” is not a formal medical label; most people use it to describe either (a) a full, doctor-confirmed PTSD diagnosis (meeting all four symptom clusters of intrusion, avoidance, negative mood/thoughts, and hyper-arousal) rather than a few stray symptoms, or (b) Complex PTSD, a newer ICD-11 diagnosis that includes all the usual PTSD features plus persistent problems with emotion control, negative self-view, and relationships after prolonged or repeated trauma. In short, standard PTSD focuses on how a single or short-lived traumatic event is re-experienced, whereas “clinical/complex” PTSD implies either full diagnostic severity or an added layer of long-term self-and-relationship difficulties—something a qualified mental-health professional can sort out and treat with trauma-focused therapy and, when needed, medication.

Does complex PTSD ever go away?

Complex PTSD can and often does get much better—many people reach full remission or only occasional, manageable flare-ups once they’ve had consistent, trauma-focused treatment (such as EMDR, TF-CBT, or a phase-based approach that first builds safety skills and then processes the trauma). How long that takes varies; factors like the length of the original abuse, other mental-health conditions, and access to supportive relationships and specialized care influence recovery, which is why some people need longer-term therapy or periodic “tune-ups.” In short, the condition isn’t necessarily lifelong, but viewing it as a journey—with professional help, skills practice, and a strong support network—gives the best odds of lasting relief.

Why is EMDR controversial?

Controversy arises from three fronts: first, although many studies now show EMDR can reduce post-traumatic stress as well as traditional exposure therapies, earlier weak studies and some mixed results planted doubt. Second, research shows the eye movements themselves may add little beyond standard exposure, so experts argue over the true mechanism and whether the name oversells a simple idea. Third, professional bodies only “conditionally” recommend EMDR and warn that brief weekend trainings can produce under-qualified providers, leading some clinicians to view it as over-marketed. Understanding these evidence, mechanism, and training debates explains why opinions on EMDR still differ.

Does PTSD count as a disability?

Yes. PTSD is legally treated as a disability whenever its symptoms are documented to substantially limit major life activities: Social Security can grant cash benefits, the VA can award a disability rating for service-connected stress, and the ADA requires employers to offer reasonable job accommodations. Collect medical records that show both a formal PTSD diagnosis and how it disrupts work, school, or daily tasks—the same principle applies in most other countries’ disability systems.

How to heal from trauma without therapy?

Begin by checking safety: if you’re having thoughts of self-harm, losing touch with reality, or using substances to cope, call a crisis line (e.g., 988 in the U.S.) or seek professional help. Otherwise, think of recovery in three daily practices—steady your body (slow breathing, walking, yoga), give the story gentle airtime (15-minute journaling or a free app like PTSD Coach), and reconnect with supportive people and purposeful activities—while tracking sleep, mood, and triggers each week to see progress. If symptoms stay the same or worsen after a couple of months of consistent effort, that’s your signal to add a trained therapist, group program, or tele-health option.

What diagnosis is close to PTSD?

The diagnosis most often mistaken for PTSD is Acute Stress Disorder—symptoms can look identical, but they start within days of the trauma and fade within a month; if they last longer, the label changes to PTSD. Clinicians also consider Complex PTSD (a longer-term form after chronic abuse), Adjustment Disorder (stress-triggered distress without flashbacks), and common anxiety or depression disorders that share sleep, mood or panic problems but are not tied to a specific traumatic memory. A mental-health professional sorts these out by asking about the kind of event that happened, how long symptoms have lasted, and whether true “re-experiencing” (flashbacks or nightmares of the trauma) is present.

Why is PTSD so hard to treat?

PTSD is tough to heal because severe stress literally rewires the brain’s alarm and memory centres, every person’s trauma history is different, and the core symptoms (avoidance, distrust, numbness) make it hard to start or stay in treatment. Recovery therefore usually requires a personalised mix of approaches—such as trauma-focused therapy, medication, and skills for sleep and safety—and patience while you and your clinician adjust the plan. The good news is that most people do improve, and newer tools like EMDR, virtual-reality exposure, ketamine or MDMA-assisted therapy are widening the options when first-line methods fall short.

Does Stellate ganglion block work for PTSD?

A stellate ganglion block can quiet the “fight-or-flight” nerves, and small studies—mainly in military populations—show it can lessen PTSD symptoms in roughly half of patients for a month or two; other trials have found no clear benefit, so results are mixed. Because evidence is still limited and short-term, specialists usually offer SGB only as an adjunct to proven treatments (therapy, medications) after weighing its brief relief against the need for repeat injections and the procedure’s small but real risks (infection, hoarse voice, temporary eyelid droop). Discussing it with a trauma-focused mental-health provider and an experienced pain or anesthesia physician can help decide if this experimental option makes sense in your overall care plan.

Popular Searches

By Condition

Depression Clinical Trials in Florida

Anxiety Clinical Trials in Florida

Schizophrenia Clinical Trials in Florida

ADHD Clinical Trials in Florida

Bipolar Disorder Clinical Trials in Florida

Multiple Sclerosis Clinical Trials in Florida

Autism Clinical Trials in Florida

Treatment Resistant Depression Clinical Trials in Florida

Borderline Personality Disorder Clinical Trials in Florida

Social Anxiety Disorder Clinical Trials in Florida

Parkinson's Disease Clinical Trials in Florida

Alzheimer's Disease Clinical Trials in Florida

By Location

Clinical Trials near Miami, FL

Clinical Trials near Tampa, FL

Clinical Trials near Jacksonville, FL

Clinical Trials near Orlando, FL

Clinical Trials near Gainesville, FL

Clinical Trials near West Palm Beach, FL

Clinical Trials near Fort Lauderdale, FL

Clinical Trials near Clearwater, FL

Clinical Trials near Fort Myers, FL

Clinical Trials near Hollywood, FL

Clinical Trials near Sarasota, FL

Clinical Trials near Hialeah, FL

Other People Viewed

By Subject

Top Post-Traumatic Stress Disorder Clinical Trials near Miami, FL

8 Post-Traumatic Stress Disorder Trials near Tampa, FL

Top Post-Traumatic Stress Disorder Clinical Trials

Top Post-Traumatic Stress Disorder Clinical Trials near Glendale, AZ

Top Post-Traumatic Stress Disorder Clinical Trials near Anaheim, CA

Top Post-Traumatic Stress Disorder Clinical Trials near Irvine, CA

Top Post-Traumatic Stress Disorder Clinical Trials near San Diego, CA

Top Post-Traumatic Stress Disorder Clinical Trials near Los Angeles, CA

Top Post-Traumatic Stress Disorder Clinical Trials near Ventura, CA

Top Clinical Trials near Fort Lauderdale, FL

Top Schizophrenia Clinical Trials near Fort Lauderdale, FL

Top Diabetes Clinical Trials near Fort Lauderdale, FL

By Trial

Methylphenidate for Post-Traumatic Stress Disorder

Brazilian Jiu Jitsu vs. Yoga for PTSD

Ketamine-Enhanced Psychotherapy for PTSD

Stress Management for Caregiver Stress

Brain Stimulation for PTSD

Stress and Blood Pressure Management for Caregivers

Erenumab for Post-Traumatic Headache

TRRP for Traumatic Injury in Adolescents

HIV/HCV Testing for Substance Use Disorder

Telehealth Mindfulness for Post-Surgical Pain

Antithrombin for Traumatic Injury-related Blood Clots

Physical Therapy for Traumatic Brain Injury

Related Searches

Top Post-traumatic-stress-disorder Clinical Trials near Irvine, CA

Top Schizophrenia Clinical Trials near Fort Lauderdale, FL

Top Schizophrenia Clinical Trials near Irvine, CA

Top Clinical Trials near Newport Beach, CA

Full Body Radiographs for Skeletal Structure Analysis

AZD4604 for Asthma

3D Ultrasound-Guided Brachytherapy for Gynecologic Cancers

Wisconsin Ginseng for Cancer Fatigue

2-Step Stem Cell Transplant for Blood Cancers

Influenza Vaccine for Flu

Top Clinical Trials near Brighton, MA

Top Weight-loss Clinical Trials near New York, NY

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial